Schizophrenia Bulletin Advance Access originally published online on September 15, 2005
Schizophrenia Bulletin 2005 31(4):954-961; doi:10.1093/schbul/sbi059
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2005.
A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICS Project
Robert Wood Johnson Clinical Scholars Program
Greater Los Angeles VA Healthcare System and the University of California, Los Angeles
To whom correspondence should be addressed; mail: 911 Broxton Plaza, Third Floor, Los Angeles, CA 90024, phone: (310) 794-2268, e-mail: ebromley{at}ucla.edu.
Introduction: In 2002, the National Institute of Mental Health (NIMH) initiated a multistakeholder research process designed to stimulate the development and evaluation of medications targeting the cognitive deficits associated with schizophrenia. The first phase, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), sought consensus on laboratory measures for cognition, clinical trial outcome measures, and drug registration requirements. MATRICS constitutes a unique drug development model because it targeted a specific endophenotype of schizophrenia and because it engaged academic, industry, and government stakeholders in a consensus-oriented process. This study offers a preliminary qualitative evaluation of the NIMH-MATRICS project. Method: Interview data are used to describe how MATRICS participants regard 3 aspects of the development of cognitive medications: the definition of the treatment target, stakeholders' role in the early development process, and anticipated dissemination complexities. Results: MATRICS participants describe the treatment target in highly varied ways and envision a wide range of public health benefits. MATRICS is perceived as inclusive, despite minimal representation from some end users. According to informants, clinical detection, documentation, and monitoring of cognition and functioning may prove problematic. More thoroughly than non-industry-employed informants, industry-employed MATRICS participants articulate strategies by which treatments can be integrated into clinical practice. Discussion: The MATRICS process did not produce a clinical concept of cognitive impairment in schizophrenia, and significant challenges remain to be addressed regarding the rational clinical use of novel pharmaceuticals for cognition. Broader inclusion of end users in translational science projects may streamline implementation and facilitate improvements in real-world outcomes.
Keywords: schizophrenia / cognition / psychotropic drugs, therapeutic use / diffusion of innovation / qualitative research
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. S. Stone and L. J. Seidman Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function Schizophr Bull, January 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bromley Clinicians' Concepts of the Cognitive Deficits of Schizophrenia Schizophr Bull, May 1, 2007; 33(3): 648 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bromley Barriers to the Appropriate Clinical Use of Medications That Improve the Cognitive Deficits of Schizophrenia Psychiatr Serv, April 1, 2007; 58(4): 475 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Brekke, K. Ell, and L. A. Palinkas Translational Science at the National Institute of Mental Health: Can Social Work Take Its Rightful Place? Research on Social Work Practice, January 1, 2007; 17(1): 123 - 133. [Abstract] [PDF]
|
|